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1. Introduction
Parkinson’s disease (PD) is a severe deliberating neurodegenerative disease resulting from
progressive and massive cell death of dopaminergic (DA) neurons in the substantia nigra
[1]. While cell therapy strategy is strongly suggested for clinical cure of PD and DA progeni‐
tors are identified at different developing stages of midbrain, full understanding of key cell
signaling or mechanism in controlling of DA neuronal differentiation from neural stem cells
in vivo raises a great interest in cell therapeutic application for PD [2, 3]. A growing line of
studies has shown that Wnts are lipid-modified factor for stem cell growth and cell differen‐
tiation and regulate midbrain DA neuronal development and hippocampal neurogenesis
through both canonical and non-canonical Wnt signaling pathways [4-7]. The canonical
Wnt/β-catenin signaling appeals a key mechanism in controlling DA neuronal fate decision
from neural stem cells or progenitors in the ventral midbrain during embryonic develop‐
ment and adulthood [8]. This chapter has focused on fast growing knowledge on Wnt/β-cat‐
enin signaling pathway, intracellular cascade or crosstalk, functional roles in controlling DA
neuronal fate decision and neural repair under physiological development and pathological
events, and potential manipulation of Wnt/β-catenin signaling pathway as cell therapeutic
target for treatment of PD in human beings.
2. The Wnt/β-catenin signaling pathway
The Wnt signaling pathway, conserved from low animals to primates, was originally identi‐
fied as the morphogenic signaling for organogenesis. Among three branches of Wnt signal‐
© 2013 Chen; licensee InTech. This is an open access article distributed under the terms of the Creative
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ing pathways, the best studied one is the canonical Wnt pathway, which is highlighted by β-
catenin-dependent regulation of down-streaming genes. The canonical Wnt ligands, e.g.
Wnt1, Wnt2 and Wnt3a, can be secreted by surrounding neuronal and glial cells in the nerv‐
ous system, bind to Frizzled and Lrp5/6 receptors in the target cells. At absence of binding
with ligand Wnts, a protein complex in the cytoplasm, namely Axin2/GSK3β/APC complex
makes phosphorylation of β-catenin and degradation of phosphorylated β-catenin, and
keeps cytoplasmic β-catenin at such a low level that β-catenin can not be translocated into
nucleus. Upon Wnt stimulation, the Axin2/GSK3β/APC complex can be deaggregated, the
cytoplasmic β-catenin is accumulated and increased β-catenin imported into nucleus. In the
nucleus, β-catenin is recruited by transcription factors TCF1-4 to the promoter regions of the
target genes for specific biological effects. These TCF-4 downstream targeting genes include
c-myc, mmp-7, cyclin D1, CD44 that are actively and mainly involved in cell proliferation,
cycling and cell differentiation (Figure 1). On the other hand, the non-canonical Wnt signal‐
ing pathways, i.e. PCP pathway and Ca2+ pathway, Wnt ligands bind to Frizzled receptors,
then activate GTPase or increase intracellular Ca2+, transmitting signals by JNK cascade or
without any nucleus events [4-6].
Figure 1. The canonical Wnt/β-catenin signaling pathway in regulation of downstream target genes of DA neurogen‐
esis (From Ref. 48, Ding, et al., 2011)
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3. Role of Wnt/β-catenin signaling in facilitating DA neuronal
development
The canonical Wnt/β-catenin signaling pathways is critical for generation of DA neurons during
development. Differential regulation of midbrain DA neurogenesis by Wnt1, Wnt3a, and Wnt5a
was well studied [9]. The β-catenin was detected in DA precursor cells and β-catenin signaling
took place in the precursor cells by assessment of TOPgal reporter mice. Wnt3a promoted prolif‐
eration of precursor cells expressing the orphan nuclear receptor-related factor 1 (Nurr1) but did
not increase the number of DA neurons. The Wnt1 and Wnt5a increased the number of midbrain
DA neurons in E14.5 possibly by two mechanisms. Wnt1 predominantly increased the prolifera‐
tion of Nurr1+ precursors that acquired a neuronal DA phenotype, up-regulated cyclins D1 and
D3, and down-regulated p27 and p57 expression. In contrast, Wnt5a increased proportion of
Nurr1+ precursors and up-regulated expression of Ptx3 and c-ret mRNA. Moreover, the soluble
cysteine-rich domain of Frizzled-8 (a Wnt inhibitor) blocked endogenous Wnts and effects of
Wnt1 and Wnt5a on proliferation and acquisition of DA phenotype. For the embryonic expres‐
sion, Wnt1 was throughout of midbrain at E8.5, and then restricted to the roof plate, a subset of
floor plate cells and isthemus of midbrain at E9.5. From E10 to E12, Wnt2 was observed in the ven‐
tral midbrain, with highest in the intermediate and marginal zone of ventral midbrain. Wnt3a
was expressed in dorsal midbrain of rat at E11.5. The Wnt5a appeared at E9.5 and became restrict‐
ed to the floor plate of midbrain from E11.5 to E13.5. Functionally, mutation of Wnt1 led to re‐
duced DA neurons in late embryos. Mechanistic study showed that Wnt1 and its downstream
gene Lmx1 formed a loop to regulate the expression of Octx2, Nurr1 and Pitx3, thereby establish‐
ing identity of DA precursors in vivo [10]. This Wnt1-lmx1a regulatory loop synergistically con‐
trolled DA differentiation in the midbrain by antagonizing Shh signaling pathway [11]. Wnt 2
mutation resulted in a decrease in proliferation of DA progenitors and subsequently loss of DA
neurons, partially by phosphorylation of Lrp5/6 and Dishevelled 2/3. Wnt 3a promoted the pro‐
liferation of Nurr1-positive DA progenitors. The Wnt5a, derived by the astrocytes and radial
glial cells, was demonstrated to promote cell fate commitment of precursors into DA neurons
and development of A9-A10 DA neurons in vivo [12, 13]. The Wnt5a also regulated DA axon
growth and guidance in midbrain development [14]. In mouse embryo at E11.5, Wnt5a was
abundantly expressed in the ventral midbrain where it promoted DA neurite and axonal growth.
By E14.5, when DA axons were approaching their striatal target, Wnt5a caused DA neurite re‐
traction. Co-culture of ventral midbrain explants with Wnt5a-overexpressing cell aggregates re‐
vealed that Wnt5a was capable of repelling DA neurites. Antagonism experiments revealed that
the effects of Wnt5a were mediated by the Frizzled receptors and by small GTPase, Rac1. More‐
over, this effect was specifically blocked by Wnt5a antibody. Role of Wnt5a in DA neuronal axon
morphogenesis was further verified in Wnt5a-/-mice, where fasciculation of the medial fore‐
brain bundle as well as the density of DA neurites and striatal terminals were disrupted. Al‐
though Wnts can function via intracellularβ-catenin, Ca2+, and JNK signaling, the canonical
Wnt/β-catenin signaling pathway shows a major position in regulation of DA neurogenesis. It
appeared that all Wnt1, Wnt3a and Wnt5a act in proliferation and DA differentiation of precur‐
sor cells with sequence of proliferation stimulating effect of Wnt1≥Wnt3a≥Wnt5a, or differentia‐
tion facilitating effects of Wnt5a≥Wnt1≥Wnt3a. These findings have evidenced that the Wnt/β-
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catenin signaling is a key regulator of proliferation and differentiation of DA precursors and
different Wnts might have specific and unique activity profiles during DA neurogenesis.
Dynamic temporal and cell type-specific expression of Wnt signaling components was
found in the developing midbrain [15]. The DA neuronal cluster size was determined dur‐
ing early forebrain patterning [16]. Furthermore, temporally controlling modulation of
FGF/ERK signaling directed midbrain DA neural progenitor fate in mouse and human pluri‐
potent stem cells [17]. Dickkopf-1 (Dkk1), a specific Wnt signaling inhibitor, regulated ven‐
tral midbrain DA neuronal differentiation and morphogenesis [18]. Blockade of Wnt/β-
catenin signaling pathway promoted neuronal induction and DA-phenotype differentiation
in embryonic stem cells [19]. Delayed DA neuron differentiation was seen in the Lrp6 mu‐
tant mice [20]. Signaling interactions between Wnt/β-catenin and sonic hedgehog (Shh)
mechanisms functioned to regulate the production of DA neurons. Specific deletion of intra‐
cellular β-catenin in Shh expressing cells resulted in diminished DA progenitors, NgN2,
BrdU labeling cells, and subsequently DA neurons. Permanent stabilization of β-catenin in
Shh expressing cells led to more DA progenitors and DA neurons accordingly, and inhibi‐
tion of GSK-3β also increases the differentiation of DA precursors [21]. HPRT deficiency co‐
ordinately dysregulated canonical Wnt signaling in neuro-developmental regulatory
process [22]. Wnts showed antagonism of Shh signaling pathway and facilitated neurogene‐
sis in the midbrain floor plate [23]. The β-arrestin was also a necessary component of Wnt/
beta-catenin signaling linking Dvl and axin in vitro and in vivo functions [24]. Wnt5a induced
the DA differentiation of midbrain neural stem cells in vitro, and the effect was mediated by
the phosphorylation of Dishevelled protein and activation of GTPase RAC1. Wnt5A stimu‐
lated the GDP/GTP exchange at pertussis toxin-sensitive heterotrimeric G proteins [25]. As
to Wnt receptors, mutation of Lrp6 might not affect the patterning; proliferation and cell
death in the ventral midbrain, but displayed a delay in the onset of DA precursor differen‐
tiation. Lrp6(-/-) mice exhibited 50% reduction in DA neurons and expression of DA mark‐
ers such as Nurr1 and Pitx3 as well as a defect in midbrain morphogenesis in the mutant
embryos at E11.5. The extracellular domain of Lrp5/6 inhibited the non-canonical Wnt sig‐
naling in vivo condition [26]. The mitogen-activated protein kinases promoted Wnt/β-catenin
signaling via phosphorylation of LRP6 [27]. Ectopic Wnt/β-catenin signaling was also in‐
volved in induction of neurogenesis in spinal cord [28]. In addition, Wnt5a was required for
the endothelial differentiation of embryonic stem cells and vascularization via both Wnt/β-
catenin signaling and protein kinase C pathways [29].
4. Role of Wnt/β-catenin signaling in DA neural plasticity or repair in
adulthood
The Wnt/β-catenin signaling pathway also actively functions in neural plasticity and repair
of DA neurons in the midbrain of disease conditions Interestingly, the crosstalk between
Wnt/β-catenin signaling and inflammatory was observed in plasticity of subventricular zone
progenitors in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of
PD, suggesting its involvement in consequences for neuroprotection and functional repair
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[30]. Accumulating evidence indicated that a population of astrocyte was functionally acti‐
vated, named reactive astrocytes with active proliferation, morphological expanding of cell
bodies and increasing generation of various neurotrophic factors, and with predominate dis‐
tribution in the nigra and striatum of PD condition. These reactive astrocytes and Wnt/β-cat‐
enin signaling showed a link of nigrostriatal injury to repair in MPTP model of PD. The Wnt
signaling components Frizzled-1 and β-catenin were dynamically regulated in response to
MPTP insult-induced DA neuronal degeneration and reactive glial activation. Activated or
reactive astrocytes in the ventral midbrain were identified as candidate source of Wnt1.
Blocking Wnt/Fzd signaling with Dkk1 also counteracted astrocyte-induced neuroprotection
against MPP (+) toxicity in primary mesencephalic astrocyte-neuron cultures. Moreover, as‐
trocyte-derived Wnt1 promoted DA neurogenesis from adult midbrain stem cells or progen‐
itor cells. Conversely, lack of Wnt1 transcription in response to MPTP in aged animals and
failure of DA neurons to recover could be reversed by activation of Wnt/β-catenin signaling
in vivo, suggesting MPTP-reactive astrocytes and Wnt1 worked as neuroprotective activity
in DA neural plasticity [31]. Obviously, Wnt1 regulated Frizzled-1/β-catenin signaling path‐
way as a candidate regulatory circuit for DA neuron-astrocyte crosstalk in the ventral mid‐
brain, also implying that Wnt signals might act as the critical messages in neuron-glial
intercommunication in the adult mammalian nervous system [32].
Moreover, The Wnt/β-catenin signaling also involved in Parkin protection of DA neurons [33].
Differential expression of Wnts was observed after spinal cord contusion injury in adult ro‐
dents [34]. Wnt signaling in the activated microglia; cells exhibited proinflammatory effect.
Gene-expression profiling revealed that Wnt3A specifically increased expression of proinflam‐
matory immune response genes in microglia and exacerbated release of IL-6, IL-12, and tumor
necrosis factor α [35]. Heterotrimeric G protein-dependent Wnt5A signaling to ERK1/2 mediat‐
ed distinct aspects of proinflammatory transformation in microglial cells [36]. While combin‐
ing  nitric  oxide  release  with  anti-inflammatory  activity  preserved  DA  innervation  and
prevented motor impairment in the MPTP model of PD [37], switching the microglial harmful
phenotype promoted lifelong restoration of DA neurons from inflammatory degeneration in
the substantia nigra of aged mice [38]. In addition, activation or inhibition of Wnt/β-catenin sig‐
naling could regulate neuronal and glial differentiation in neurospheres, respectively. Inhibi‐
tion of Wnt signaling promoted gliogenesis from neural stem cells. Long-term activation of
Wnt signaling pathway by Wnt-7a or GSK3 inhibitors promoted a moderate increase of neuro‐
nal differentiation and blocked gliogenesis. In contrast, Wnt pathway inhibition by Dkk1over-
expression robustly increased gliogenesis [39]. Accumulating evidences suggested that the
glial cells including reactive astrocytes and microglial cells might present as crucial turning
points for the therapeutic strategy against PD [40, 41]
5. Prospect on manipulation of Wnt/β-catenin signaling for regeneration
medicine
The studies have indicated that transplantation of Wnt primed neural stem cells might result
in improvements of cellular and functional recovery in PD condition. The midbrain neural
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stem cells with Wnt5a-treatment showed beneficial effect for DA cell replacement therapy in
parkinsonian animal model [42], and purified Wnt5a increased dishevelled phosphorylation
and DA neuronal differentiation in the midbrain [43]. Both GSK-3β inhibition and β-catenin
stabilization increased commitment into DA neurons of neural precursors in the ventral
midbrain [44], and the application of GSK-3β inhibitor lithium also influenced DA differen‐
tiation potential of human NT2 cells [45]. Generation of DA phenotype in neural stem cells
could be carried out by engineering Nurr1 and Wnt signals [46]. Wnts also showed regulat‐
ing role on differentiation of noradrenergic neuronal precursors in locus coeruleus [47]. In
addition, the functional involvement of Wnt/β-catenin signaling pathway in link of reactive
astrocytes and plasticity or repair of nigrostriatal system further suggests Wnt/β-catenin sig‐
naling as neuroprotection therapeutic targets [30, 31]. It is hopefully that DA differentiation
of the neural stem cells and the nigrostriatal plasticity may be effectively and specifically en‐
hanced or improved by manipulation targeting on Wnt/β-catenin signaling pathway [48].
6. Summary
Although the DA neuronal cell commitment from neural stem cells or progenitor cells is
highly complicated and precisely regulated process, the canonical Wnt/β-catenin pathway
shows a critical role in controlling differentiation of DA neurons in the ventral midbrain
during development and plasticity or neural repair in adulthood. In addition, Wnt singling
might also act via Ca2+, JNK signaling and function candidate messages in DA neuron-glial
cross-talk as well. Taken together, it is hopefully expected that molecular target manipula‐
tion of Wnt/β-catenin signaling cascades will benefit controlling of DA neurogenesis and es‐
tablishing novel cell therapy for PD in human beings.
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